Avicanna Inc.: Medical Marijuana Sales Reach Record 713% YoY Growth In Q3, Introduces New Platform
Benzinga
Published Nov 15, 2023 01:56
Updated Nov 15, 2023 03:10
Avicanna Inc.: Medical Marijuana Sales Reach Record 713% YoY Growth In Q3, Introduces New Platform
Benzinga - by Nicolás Jose Rodriguez, Benzinga Staff Writer.
Avicanna Inc. (OTCQX: AVCNF) a biopharmaceutical company specializing in proprietary cannabinoid-based products, announced Q3 2023 results late Tuesday, highlighted by the successful acquisition of Medical Cannabis by Shoppers assets, paving the way for the launch of the innovative MyMedi.ca platform.
Leadership Insight Aras Azadian, CEO of Avicanna Inc., emphasized the company's strategic vision. "We had the boldness to take on the challenge of acquiring the Medical Cannabis by Shoppers business and executed on integrating it into the newly developed MyMedi.ca" he stated.
The goal is to provide a comprehensive medical cannabis care platform, enhancing accessibility for Canadian patients while maintaining a focus on evidence-based medical applications of cannabinoids.
Phil Cardella, CFO, expressed pride in achieving the milestone of an eight-digit revenue figure for the first time in the company's history. He credited the substantial increase in high-margin revenue to Avicanna's innovation and commercial platforms, anticipating sustained efforts toward growth, profitability, and self-reliance.
Financial Highlights
- Avicanna reported record revenue of $6.27 million for Q3 2023, marking a 90% increase from the previous quarter and a 713% surge year-over-year.
- The 9-month revenue of $10.7 million represents a significant 269% growth compared to the same period last year.
- Despite a notable increase of 23% in SG&A over the nine-month period, the company demonstrated the scalability of its business model.
The company also reported achieving improved consolidated gross margins of 47% through operational enhancements.
Photo by Dr.Sourabh Panari on Unsplash.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article on Benzinga
Get The App
Written By: Benzinga
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.